Table 2.
Current non-VEGF targets in clinical trials
| Drug | Drug target | Disease target | Clinicaltrials.gov ID | Phase | Number patients |
|---|---|---|---|---|---|
| Fractalkine (FKN) | CX3C chemokine | PDR | NCT00728598 | 1, completed 1998 | 30 |
| OC-10X | tubulin inhibitor | PDR, AMD | NCT01869933 | 1 | 10 |
| Fovista (E10030) | Anti-PDGF-B | AMD |
NCT02591914 NCT02214628 NCT01089517 NCT01944839 |
1 2 2 3,R |
25 100 449 622 |
| Palomid 529 | TORC1/2inhibitor of mTOR | AMD |
NCT01033721 NCT01271270 |
1 1 |
13 5 |
| AdGVPEDF.11D | PEDF | AMD | NCT00109499 | 1 | |
| Sirolimus | mTOR IL-2 | AMD | NCT00766337 | 2 | 62 |
| Everolimus (RAD001) | mTOR | AMD | NCT00857259 | 2 | 16, terminated |
| PF-04523655 | Block RTP801 mTOR | DME AMD |
NCT01445899 NCT00713518 |
2 2 |
258 152 |
| ARC1905 | Inhibit complement C5 aptamer | AMD | NCT00709527 | 1 | 60 |
| iSONEP | S1P lipid | AMD | NCT01414153 | 2 | 158 |
| ASP8232 | Vascular adhesion protein-1 inhibitor | DME | NCT02302079 | 2 | 96 |
| hI-con1 | Factor VIIa inhibitor | AMD | NCT02358889 | 2 | 88 |
| Tocilizumab | Antibody IL-6 | DME | NCT02511067 | 2 | 66 |
| iCo-007 | inhibitor C-raf | DME | NCT01565148 | 2 | 208 |
| Pf-04634817 | CCR2/5 antagonist | DME | NCT01994291 | 2 | 212 |
| ATG003 (mecamylamine) | Tubulin depolymerize, tight junction disruption | AMD | NCT00607750 | 2 | 60 |
| RO6867461 | DME AMD |
NCT02699450 NCT01941082 |
2 1 |
150, R | |
| Luminate (ALG-1001) | αVβ3 and αVβ5 integrin inhibitor | DME | NCT02348918 | 2 | 150 |
| Apremilast (CC-10004) | Inhibit PDE4 (breaks down cAMP) | Behcet’s |
NCT00866359 NCT02307513 |
2 3 |
111 204 |
| Efalizumab | Bind CD11a | DME | NCT00676559 | 1 | 0, Withdrawn |
| Zimura | Anti-C5 Aptamer) | Polypoidal | NCT02397954 | 2 | 5 |
| AKB-9778 | Tie-2 activator | DME | NCT02050828 | 2 | 144 |
| AL-78898A | Complement C3 inhibitor | AMD | NCT01157065 | 2 | 99 |
| Volociximab | α5β1 integrin antagonist | AMD | NCT00782093 | 1 | 63 |
| JSM6427 | α5β1 integrin antagonist | AMD | NCT00536016 | 1 | 36 |
Abbreviations: R= recruiting; AMD = neovascular age-related macular degeneration; DME = diabetic macular edema; PDR = proliferative diabetic retinopathy; RVO = retinal vein occlusion